Developing nanoparticle drug carriers

Pharmaceutical Technology Europe

Volumn 19, Issue 1, 2007, Pages 35-42

  Vauthier, Christine ^a   Couvreur, Patrick ^b  

^a CNRS   (France)

^b UNIV PARIS SUD   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPICILLIN; ANTISENSE OLIGONUCLEOTIDE; CHITOSAN; COPOLYMER; CREMOPHOR; CYANOACRYLATE DERIVATIVE; CYCLOSPORIN A; DOXORUBICIN; HALOFANTRINE; HUMAN GROWTH HORMONE; INDOMETACIN; INSULIN; KETOPROFEN; MACROGOL; NANOCAPSULE; NANOCARRIER; NUCLEIC ACID; PACLITAXEL; PEPTIDE; POLYCAPROLACTONE; POLYISOHEXYLCYANOACRYLATE; POLYLACTIDE; PROTEIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SAQUINAVIR; SMALL INTERFERING RNA; SOLID LIPID NANOPARTICLE; TAMOXIFEN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTICLE; AUTOIMMUNE DISEASE; CANCER; CLINICAL TRIAL; CONTROLLED DRUG RELEASE; DRUG BIOAVAILABILITY; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG INDICATION; DRUG SAFETY; GRAFT REJECTION; HUMAN; INFECTION; INFLAMMATION; LIVER CELL CARCINOMA; METABOLIC DISORDER; NANOENCAPSULATION; NANOTECHNOLOGY; PAIN; PARTICLE SIZE; UNSPECIFIED SIDE EFFECT;

EID: 33846303168     PISSN: 01646826     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (63)

1. R. Aston et al., Pharm. Technol. Europe, 17(4), 21-28 (2005).
2. S.M. Moghimi, A.C. Hunter and J.C. Murray, FASEB J., 19, 311-330 (2005).
3. P. Couvreur and C. Vauthie, Pharm. Res., 23,1417-1450 (2006).
4. S.A. Wissing, O. Kayser and R.H. Muller, Adv. Drug Deliv. Rev., 30,1257-1272 (2004).
5. M. Radtke, E.B. Souto and R.H. Muller, Pharm. Technol. Europe., 17(4), 45-50 (2005).
6. D. Hoarau et al., Pharm. Res., 21,1783-1789 (2004).
7. S. Peltier et al., Pharm. Res., 23, 1243-1250 (2006).
8. O. Boussif et al., Proc. Natl. Acad. Sci. USA., 92, 7297-7301 (1995).
9. A. El-Aneed, J. Contr. Release, 94, 1-14 (2004).
10. Y. Kakizawa, S. Furukawa and K. Kataoka, J. Contr. Release, 97, 345-356 (2005).
11. C. Vauthier, E. Fattal and D. Labarre, "From polymer chemistry and physicochemistry to nanoparticulate drug carrier design and applications," in M.J. Yaszemski et al., Eds., Biomaterial Handbook - Advanced Applications of Basic Sciences and Bioengineering (Marcel Dekker, Inc, New York, NY, USA, 2004), pp 563-598.
12. P. Couvreur et al., Crit. Rev. Ther. Drug. Carrier Syst., 19, 99-134 (2002).
13. C. Vauthier and P. Couvreur, "Development of nanoparticles made of polysaccharides as novel drug carrier systems," in D.L. Wise, Ed., Handbook of Pharmaceutical Controlled Release Technology (Marcel Dekker, Inc., New York, NY, USA, 2000), pp 413-429.
14. K.A. Janes, P. Calvo and M.J. Alonso, Adv. Drug Deliv. Rev., 47, 83-97 (2001).
15. C. Passirani et al., Pharm. Res., 15, 1046-1050 (1998).
16. K. Avgoustakis, Cur. Drug Deliv., 1, 321-333 (2004).
17. G. Gaucher et al., J. Contr. Release., 109, 169-188 (2005).
18. A. Vonabourg et al., Biomaterials, 27, 4356-4373 (2006).
19. L. Nobs et al., J. Pharm. Sci., 93, 1980-1992 (2004).
20. G.S. Kwon, Crit. Rev. Ther. Drug Carrier Syst., 20, 357-403 (2003).
21. V.R Torchilin, Pharm. Res., 16 November 2006, (Epub ahead of print).
22. T. Trimaille et al., Int. J. Pharm., 319(1-2), 147-154, 2006.
23. A. Sparreboom, S.D. Baker and J. Verweij, J. Clin. Oncol., 23, 7765-7767 (2005).
24. C. Vauthier et al., Adv. Drug Deliv. Rev., 55, 519-548 (2003).
25. C. Vauthier et al., J. Contr. Release, 93, 151-160 (2003).
26. S.V. Vinogradov et al., J. Contr. Release, 107, 143-157 (2005).
27. J.F. Dufour-Lamartinie et al., 12th International symposium on viral hepatitis and liver disease (Paris, France, 1-5 July 2006).
28. J. Panyam and V. Labhasetwar, Adv. Drug Deliv. Rev., 55, 329-347 (2003).
29. C.G. Oster et al., Pharm. Res., 21, 927-931 (2004).
30. S. Kommareddy, S.B. Tiwari and M.M. Amiji, Technol. Cancer Res. Treat., 4, 615-625 (2005).
31. M. Koping-Hoggard, A. Sanchez and M.J. Alonso, Expert Rev. Vaccines., 4,185-196 (2005).
32. M.K. Basu and S. Lala, Curr. Mol. Med., 4, 681-689 (2004).
33. L.Y. Qiu and Y.H. Bae, Pharm. Res., 23,1-30 (2006).
34. M.E. Martinez Barbosa et al., Biomncromolecules,5,137-143 (2004).
35. Y.I. Jeong et al., Int. J. Pharm., 296,151-161 (2005).
36. F. Checot et al., Langmuir, 21,4308-4315 (2005).
37. P. De Jaeghere et al., J. Contr. Release, 68, 291-298 (2000).
38. A.T. Florence, J. Drug Target, 12, 65-70 (2004).
39. S.A. Galindo-Rodriguez et al., Eur. J. Pharm. Sci., 23(4-5), 357-367 (2005).
40. R. Gref, J. Contr. Release, 111, 316-324 (2006).
41. B.Y. Shekunov, Pharm Res., 23,196-204 (2006).
42. M. Greindl and A. Bernkop-Schnürch, Pharm. Res., Accepted for publication.
43. R. Gref et al., Colloid Surface. B: Biointerfaces, 18, 301-313 (2000).
44. I. Bertholon, C. Vauthier and D. Labarre, Pharm. Res., 23, 1313-1373 (2006).
45. G. Barratt, Cell. Mol. Life Sci., 60, 21-37 (2004).
46. H. Maeda et al., J. Contr. Release, 65, 271-284 (2000).
47. R. Gref et al., Biomaterials, 24, 4529-4537 (2003).
48. E.K. Park, S.B. Lee and Y.M. Lee, Biomaterials, 26,1053-1061 (2005).
49. L. Nobs et al., Bioconjug Chem., 17, 139-145 (2006).
50. A.R. Hilgenbrink and P.S. Low, J. Pharm. Sci., 94, 2135-2146 (2005).
51. J.A. Reddy, V.M. Allagadda and C.R Leamon, Curr. Pharm. Biotechnol., 6, 131-150 (2005).
52. H. Wartlick et al., J. Drug Target., 12, 461-471 (2004).
53. O.C. Farokhzad, J.M. Karp and R. Langer, Expert Opin. Drug Deliv., 3, 311-324 (2006).
54. D. Cunliffe, A. Kirby and C. Alexander, Adv. Drug Deliv. Rev., 57, 1836-1853 (2005).
55. C. Pegro et al., J. Contr. Release, 101, 151-162 (2005).
56. S. Mao et al., Pharm. Res., 22, 2058-2068 (2005).
57. I. Betholon et al., J. Nanosciences and Nanotechnology, in press 2006.
58. C. Mayer, Int. J. Artif. Organs., 28(11), 1163-1171 (2005).
59. H. Boudad et al., Pharma. Sci., 11, 369-375 (2001).
60. V.C. Mosqueira et al., Antimicrob. Agents Chemother., 48, 1222-1228 (2004).
61. A. Maksimenko et al., J. Pharm. Res., 20, 1565-1567 (2003).
62. L. Barraud et al., J. Hepatol., 42, 736-743 (2005).
63. A. Moreno-Aspitia and E.A. Perez, Future Oncol., 1, 755-762 (2005).